drugset / Trial / NCT01852071

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

NCT01852071

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from the bone marrow (BM) of ADA-deficient SCID infants and children following human ADA cDNA transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.

Timeline

Start
2013-08-02
Primary completion
2018-08-27
Completion
2018-08-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject EFS-ADA LV CD34+ cells Unknown Intravenous
Background Busulfan Small molecule 4 mg/kg
Background Peg-Ada Protein / enzyme biologic